8-K: Medinotec Inc. Announces 2023 Annual Shareholder Meeting and Proxy Details

Medinotec Inc. has scheduled its 2023 annual shareholder meeting for March 19, 2024, to be held virtually, with key proposals including the election of directors and the approval of the company's independent auditor.

Summary

• Medinotec Inc. will hold its 2023 annual shareholder meeting virtually on March 19, 2024, at 10:00 am ET.
• The meeting will include the election of five directors and the approval of BDO South Africa Inc. as the company's independent registered public accounting firm for the 2024 fiscal year.
• Shareholders of record as of January 10, 2024, are eligible to vote.
• There are 11,733,750 shares of common stock outstanding and entitled to vote.
• The company's board recommends voting for all director nominees and for the approval of BDO South Africa Inc.
• The proxy materials, including the notice of the annual meeting and the proxy statement, are being distributed to shareholders on or about February 27, 2024.
• Shareholders must vote by proxy before the meeting as there will be no electronic voting during the virtual meeting.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily focused on procedural matters related to the annual meeting. While there are some potential risks identified, the overall sentiment is neither overly positive nor negative.

Positives

• The company is holding its annual shareholder meeting, which is a standard corporate governance practice.
• The board is recommending the approval of the independent auditor, which is a positive sign of confidence in the firm.
• The company is providing clear instructions on how to vote and participate in the virtual meeting.
• The company has an audit committee with a financial expert.

Negatives

• There will be no electronic voting during the virtual meeting, requiring shareholders to vote by proxy in advance.
• The company has a history of related party transactions, which could raise concerns about conflicts of interest.
• The company has changed its independent auditor from Mercurius & Associates LLP to BDO South Africa Inc. in June 2023.

Risks

• The company's related party transactions, particularly loans and sales with entities controlled by the CEO, could pose a risk of conflicts of interest.
• The company's reliance on a single distributor, DISA Life Sciences, for the majority of its sales could create a risk if that relationship were to change.
• The company's loan from Minoan Medical Proprietary Limited carries interest at the prevailing prime lending rate, which could fluctuate and impact the company's financials.
• The company's financial statements are not included in this document, making it difficult to assess the company's financial health.

Future Outlook

The company has not provided any specific forward-looking statements or guidance in this document, but it does outline the process for submitting proposals for the 2024 annual meeting.

Management Comments

• The Board believes that Dr. Vizirgianakis has the experience, qualifications, attributes and skills necessary to serve on the Board because of the fact that he held similar positions for more than 10 years and his designation as a medical doctor, he is also a founding shareholder in the company and has a long-standing track record in the industry.
• The Board believes that Mr. van Niekerk has the experience, qualifications, attributes and skills necessary to serve on the Board because of the fact that he held similar positions for more than 10 years and his designation as a chartered accountant, he is also a founding shareholder in the company and has a long-standing track record in the industry.
• The Board believes Mr. Vizirgianakis industry knowledge, sales and marketing experience and his international business relationships qualify him to serve as a director.
• We have selected Mr. Spirakis to serve as an independent director because of his education, skills and experience in Biomedical Engineering, Manufacturing & Marketing / Selling of Medical Devices.

Industry Context

The announcement of the annual shareholder meeting is a standard practice for publicly traded companies. The election of directors and the appointment of an independent auditor are key corporate governance activities. The company's related party transactions are not uncommon in smaller companies but require careful scrutiny.

Comparison to Industry Standards

• The virtual format of the annual meeting is becoming increasingly common, especially for companies with international shareholders.
• The appointment of an independent auditor is a standard practice to ensure financial transparency and compliance.
• The related party transactions, while disclosed, are more common in smaller companies and may raise concerns about potential conflicts of interest.
• The company's reliance on a single distributor is not uncommon but may be a risk factor compared to companies with more diversified distribution channels.
• The company's board composition, with a mix of executive and independent directors, is generally in line with corporate governance best practices.

Corporate Governance

Related Party Transactions

• The company leases commercial buildings from Minoan Capital Proprietary Limited, owned by the CEO.
• The company has an unsecured loan from Minoan Medical Proprietary Limited, also related to the CEO.
• The company sells the majority of its stock to DISA Vascular Distribution t/a DISA Life Sciences, a distributor where the CFO previously held a non-executive director role.
• Sales were also made to Minoan Medical Proprietary Limited to build the export market.

Stakeholder Impact

• Shareholders are required to vote on the election of directors and the appointment of the independent auditor.
• Employees are subject to the company's Code of Ethics.
• The company's financial performance and governance practices impact its stakeholders, including shareholders, employees, and suppliers.
• The company's related party transactions may raise concerns among stakeholders about potential conflicts of interest.

Next Steps

• Shareholders are to vote by proxy before the March 19, 2024 annual meeting.
• The company will hold its annual shareholder meeting on March 19, 2024.
• The company will continue to operate under the direction of the elected board of directors.
• The company will be audited by BDO South Africa Inc. for the fiscal year ending February 28, 2024.

Key Dates

Keywords

Annual Meeting, Shareholders, Proxy Statement, Board of Directors, Independent Auditor, BDO South Africa Inc., Corporate Governance, Related Party Transactions, Virtual Meeting, Director Election